2006年四川省大骨节病病情调查结果分析

目的 了解四川省大骨节病病情现状.方法 对20个大骨节病病区县进行儿童右手X线检查、成人大骨节病病情调查,采集儿童发样及当地主食粮样进行含硒量检测.结果 儿童临床检出率平均为1.02%;X线检出率平均为2.12%(0～13.16%),其中10.00%及以上的病区村有13个.成人临床检出率平均为27.02%(3.34%～53.08%),其中Ⅰ度16.73%、Ⅱ度7.79%、Ⅲ度2.49%.儿童发硒水平平均为(0.289±0.079)mg/kg,粮食硒水平平均为(0.023±0.021)mg/kg.结论 四川省大部分地区儿童大骨节病病情处于控制或基本控制范围,但局部地区尚处于较高新发病水平,成人大骨节病病情较为严重.     

A hernia in the inguinal region is not always an inguinal hernia

A male patient of 60 years presented with a swelling in the left groin of 10 months duration. Past records showed bilateral lumbar sympathectomy and omentopexy done 20 and 6 years back, respectively, for Buerger’s disease. Abdominal examination revealed a huge hernial swelling in the left groin extending from the symphysis pubis to anterior superior iliac spine measuring 25 × 18 cm. On exploration, the contents were intestines and omentum, which were coming out through a defect of 5 × 3 cm in the lower fibers of the conjoint muscle 4 cm cephalad to the deep ring, a finding which made the final diagnosis as an incisional hernia. We present this interesting case as a very rare complication of omentopexy, probably not reported previously, and an unusual case of an incisional hernia presenting as an inguinal hernia which is very difficult to diagnose unless encountered before. Its rarity and clinical challenge is highlighted.     

舒张功能障碍对冠心病的诊断价值

目的应用超声多普勒方法评价冠心病患者的左室整体舒张功能及舒张功能障碍的发生率，探讨舒张功能障碍在冠心病无创诊断中的价值。方法对入选病人行常规检查，同时进行二尖瓣血流频谱、肺静脉血流频谱及二尖瓣环组织多普勒检查，对比临床标准与舒张功能障碍标准对冠心病的诊断率。结果舒张功能障碍标准对冠心病的检出率显著高于临床标准。结论舒张功能检查可作为冠心病诊断的初筛检查。     

CT导引下胸部病变穿刺活检不同方法的临床探讨

目的探讨胸部病变穿刺活检联合同轴针吸对提高阳性率减少并发症的价值。方法回顾性分析CT导引下106例胸部病变三种不同穿刺方法的阳性率及并发症。结果单纯针吸组32例,检出恶性病变23例,良性4例,阳性率为84.3%,并发症为15.6%;单纯活检组27例,检出恶性病变15例,良性7例,阳性率为81.5%,并发症为48.1%;活检同轴针吸组47例,检出恶性病变28例,良性15例,阳性率91.5%,并发症为29.7%。结论活检联合同轴针吸是提高阳性率减少并发症的较好的活检方法,它既弥补了活检的缺点,又集中了针吸的优点,是值得推广的活检方法。     

Users' subjective evaluation of electronic vision enhancement systems

The aims of this study were (1) to elicit the users' responses to four electronic head-mounted devices (Jordy, Flipperport, Maxport and NuVision) and (2) to correlate users' opinion with performance. Ten patients with early onset macular disease (EOMD) and 10 with age-related macular disease (AMD) used these electronic vision enhancement systems (EVESs) for a variety of visual tasks. A questionnaire designed in-house and a modified VF-14 were used to evaluate the responses. Following initial experience of the devices in the laboratory, every patient took home two of the four devices for 1 week each. Responses were re-evaluated after this period of home loan. No single EVES stood out as the strong preference for all aspects evaluated. In the laboratory-based appraisal, Flipperport typically received the best overall ratings and highest score for image quality and ability to magnify, but after home loan there was no significant difference between devices. Comfort of device, although important, was not predictive of rating once magnification had been taken into account. For actual performance, a threshold effect was seen whereby ratings increased as reading speed improved up to 60 words per minute. Newly diagnosed patients responded most positively to EVESs, but otherwise users' opinion could not be predicted by age, gender, diagnosis or previous CCTV experience. User feedback is essential in our quest to understand the benefits and shortcoming of EVESs. Such information should help guide both prescribing and future development of low vision devices.     

血清尿酸水平与冠心病及其危险因子关系的研究

目的:探讨血清尿酸(UA)水平与冠心病(CHD)及其相关因素关系。方法:选择经冠状动脉造影检查证实的冠心病患者187例,冠脉造影正常对照组71例,常规空腹采集静脉血测定血清UA,分析冠心病危险因子、冠状动脉病变程度、病变支数及病变类型与相应UA水平的关系。结果:CHD组的一般资料与对照组无明显差异,但血清UA水平明显高于对照组(P<0.01);在CHD组中,轻度狭窄、中度狭窄及重度狭窄,其UA水平逐渐增高,分别为(418.92±36.52),(450.84±48.65),(487.40±51.62)μmol/L(P<0.01);单支病变、双支病变和三支病变,其UA水平也增高,分别为(426.32±30.78),(455.24±35.34),(480.40±40.12)μmol/L(P<0.01);A、B和C型病变,其UA水平依次增高,分别为(425.85±35.71),(461.65±46.50),(493.41±53.24)μmol/L(P<0.01);结论:血清UA水平的增高与冠心病密切相关,是冠心病发病的危险因素。     

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

Neurturin (NTN) is a potent survival factor for midbrain dopaminergic neurons. CERE-120, an adeno-associated virus type 2 (AAV2) vector encoding human NTN (AAV2-NTN), is currently being developed as a potential therapy for Parkinson's disease. This study examined the bioactivity and safety/tolerability of AAV2-NTN in the aged monkey model of nigrostriatal dopamine insufficiency. Aged rhesus monkeys received unilateral injections of AAV2-NTN into the caudate and putamen, with each animal therefore serving as its own control. Robust expression of NTN within the nigrostriatal system was observed 8 months postadministration. (18)F-fluorodopa imaging using positron emission tomography revealed statistically significant increases in (18)F-fluorodopa uptake in the injected striatum compared with the uninjected side at 4 and 8 months. In addition, at 8 months postadministration, a significant enhancement in tyrosine hydroxylase immunoreactive fibers and an increase in the number of tyrosine hydroxylase immunoreactive cells was observed in the AAV2-NTN injected striatum compared with the uninjected side. Robust activation of phosphorylated extracellular signal-regulated kinase immunoreactivity in the substantia nigra was also observed. Histopathological analyses revealed no adverse effects of AAV2-NTN in the brain. Collectively, these results are consistent with the neurotrophic effects of NTN on the dopaminergic nigrostriatal system and extend the growing body of evidence supporting the concept that AAV2-NTN may have therapeutic benefit for Parkinson's disease.     

Skin cancers and precancerous lesions in Parkinson's disease patients.

Our objective was to evaluate the frequency of neoplastic and preneoplastic skin lesions in Parkinson's disease (PD) patients when compared with an aged-matched population. We performed a cross-sectional survey in PD patients and in an age-matched control group. Patients and controls were examined by a movement disorder specialist and a dermatologist. 150 PD patients and 146 controls were included. Thirty-five PD patients (23.3%) presented skin lesions that could be classified as neoplastic or preneoplastic vs. 20 subjects in the control group (13.7%) (OR 95%, CI 1.92 [1.05, 3.51]). However, this difference lost statistical significance when adjusted for gender (recruitment of controls was matched just for age with an over representation of males in the PD group). Twenty-nine PD patients (19%) presented actinic keratosis and basal cell carcinoma was diagnosed in 4 patients (3%). Although nonconclusive, our results are in agreement with previous studies suggesting an increased risk of skin cancer in PD patients. The frequency of actinic keratosis in PD patients and the associated risk to develop melanoma recommends its screening in future epidemiological studies.     

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.

Rotigotine is a new, non-ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine, ropinirole, or placebo. The titration period was up to 13 weeks, and there was a minimum dose-maintenance period of 24 weeks for ropinirole and 33 weeks for rotigotine. The primary endpoint was the proportion of patients with a minimum of 20% decrease in the combined Unified Parkinson's Disease Rating Scale Part II and Part III scores. The responder rate in the rotigotine group was significantly higher than in the placebo group (52% vs. 30%, P < 0.0001). Transdermal rotigotine at doses < or =8 mg/24 h did not show noninferiority to ropinirole at doses < or =24 mg/day. In a post-hoc subgroup analysis, rotigotine < or =8 mg/24 hours had a similar efficacy to ropinirole at doses < or =12 mg/day. The rotigotine transdermal patch was well tolerated. The most common adverse events were application-site reactions, nausea, and somnolence. Application-site reactions were predominantly mild or moderate in intensity. In conclusion, the rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease.